Company · Public · ENLV
Enlivex Therapeutics Ltd.
Clinical-stage company developing Allocetra, an allogeneic cell therapy intended to reprogram macrophages toward immune homeostasis. Company-reported development includes an FDA Regenerative Medicine Advanced Therapy designation in knee osteoarthritis.
Listing
Public
Ticker
ENLV
Headquarters
—
Founded
—
Technology
Allogeneic macrophage-reprogramming cell therapy
Category
Longevity thesis
If restoring macrophage homeostasis modifies age-related inflammatory disease, a single immune-directed cell therapy could apply across several inflammaging indications.
Programmes
- AllocetraPhase 2b
Knee osteoarthritis
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.